Compare MEN1 and MEN2 syndromes and a screening consideration for each.

Compare MEN1 and MEN2 syndromes and a screening consideration for each.

• A. MEN1 (parathyroid, pancreatic islet tumors, pituitary); screen with serum calcium, PTH, gastrin; MEN2 (medullary thyroid carcinoma, pheochromocytoma, parathyroid disease); screen with calcitonin, metanephrines, genetic RET testing
• B. MEN1 and MEN2 are identical in tumor spectrum
• C. MEN1 includes only parathyroid tumors; MEN2 includes thyroid disease
• D. There is no difference between MEN1 and MEN2

Answer: (A)

These syndromes are inherited endocrine tumor conditions with distinct sets of tumors and matching screening strategies. In MEN1, the classic trio is parathyroid hyperplasia, pancreatic islet cell tumors (such as gastrinomas and insulinomas), and pituitary adenomas. Screening targets these possibilities: measuring serum calcium and parathyroid hormone to detect hyperparathyroidism, and checking gastrin levels to uncover gastrinoma, with pituitary involvement monitored by appropriate hormone tests and imaging when indicated. In MEN2, the hallmark tumors are medullary thyroid carcinoma and pheochromocytoma, with parathyroid disease appearing mainly in MEN2A. Screening focuses on calcitonin to detect MTC, metanephrines to screen for pheochromocytoma, and genetic RET testing to identify familial MEN2 and guide cascade testing. The combination of specific tumor spectra and corresponding screening tests is what makes this option the best fit, whereas the other statements omit these distinct differences.

These syndromes are inherited endocrine tumor conditions with distinct sets of tumors and matching screening strategies. In MEN1, the classic trio is parathyroid hyperplasia, pancreatic islet cell tumors (such as gastrinomas and insulinomas), and pituitary adenomas. Screening targets these possibilities: measuring serum calcium and parathyroid hormone to detect hyperparathyroidism, and checking gastrin levels to uncover gastrinoma, with pituitary involvement monitored by appropriate hormone tests and imaging when indicated. In MEN2, the hallmark tumors are medullary thyroid carcinoma and pheochromocytoma, with parathyroid disease appearing mainly in MEN2A. Screening focuses on calcitonin to detect MTC, metanephrines to screen for pheochromocytoma, and genetic RET testing to identify familial MEN2 and guide cascade testing. The combination of specific tumor spectra and corresponding screening tests is what makes this option the best fit, whereas the other statements omit these distinct differences.